These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12947600)

  • 21. For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?
    Ames D; Kaduszkiewicz H; van den Bussche H; Zimmermann T; Birks J; Ashby D
    Int Psychogeriatr; 2008 Apr; 20(2):259-92. PubMed ID: 18252031
    [No Abstract]   [Full Text] [Related]  

  • 22. Metrifonate for Alzheimer's disease patients.
    Schneider LS
    J Clin Psychiatry; 2000 Mar; 61(3):218-9. PubMed ID: 10817111
    [No Abstract]   [Full Text] [Related]  

  • 23. Exploring sleep-related outcomes in patients with mild to moderate Alzheimer's disease initiating acetylcholinesterase inhibitor therapy: the Morpheus survey.
    Petiau C; Onen H; Delgado A; Touchon J
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):657-9. PubMed ID: 23649861
    [No Abstract]   [Full Text] [Related]  

  • 24. The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort.
    Behl P; Lanctôt KL; Streiner DL; Black SE
    Int Psychogeriatr; 2008 Dec; 20(6):1141-59. PubMed ID: 18606043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treating Alzheimer's disease with cholinesterase inhibitors: what have we learned so far?
    Feldman H
    Int Psychogeriatr; 2002; 14 Suppl 1():3-5. PubMed ID: 12636177
    [No Abstract]   [Full Text] [Related]  

  • 26. Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.
    Wattmo C; Wallin AK; Londos E; Minthon L
    Gerontologist; 2011 Feb; 51(1):17-27. PubMed ID: 20562471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Alzheimer's disease].
    Jedidi H; Jedidi Z; Salmon E
    Rev Med Liege; 2010 Mar; 65(3):163-8. PubMed ID: 20411822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary incontinence in people with Alzheimer's disease.
    Alcorn G; Law E; Connelly PJ; Starr JM
    Int J Geriatr Psychiatry; 2014 Jan; 29(1):107-9. PubMed ID: 24311222
    [No Abstract]   [Full Text] [Related]  

  • 29. [Influence of treatment with acetyl-cholinesterase inhibitors on psychopathological symptoms in Alzheimer's disease].
    Rösler M; Frey U
    Fortschr Neurol Psychiatr; 2002 Feb; 70(2):78-83. PubMed ID: 11823923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer's disease patients.
    Bracco L; Bessi V; Padiglioni S; Marini S; Pepeu G
    J Alzheimers Dis; 2014; 40(3):737-42. PubMed ID: 24577458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholinergic foundations of Alzheimer's disease therapy.
    Giacobini E
    J Physiol Paris; 1998; 92(3-4):283-7. PubMed ID: 9789824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The application of evidence-based principles of care in older persons (issue 5): Alzheimer's disease.
    Zarowitz BJ; Stefanacci R; Hollenack K; O'Shea T; Gruber J; Tangalos EG
    J Am Med Dir Assoc; 2007 Mar; 8(3):183-93. PubMed ID: 17349948
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical inquiries. Do patients at high risk of Alzheimer's disease benefit from early treatment?
    Holt J; Stiltner L; Wallace R; Raetz J
    J Fam Pract; 2009 Jun; 58(6):320-2. PubMed ID: 19508846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-dementia drugs.
    Allen H
    Int J Geriatr Psychiatry; 1999 Apr; 14(4):239-43. PubMed ID: 10340181
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment of Alzheimer's disease and future approaches].
    Forette F; Hauw JJ
    Therapie; 2010; 65(5):429-37. PubMed ID: 21144478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacological management of cognitive dysfunction in Alzheimer's disease.
    Vandewoude MF
    Acta Clin Belg; 1999 Oct; 54(5):306-11. PubMed ID: 10555391
    [No Abstract]   [Full Text] [Related]  

  • 37. Diagnosis and treatment of Alzheimer's disease.
    Grossberg GT
    J Clin Psychiatry; 2003; 64 Suppl 9():3-6. PubMed ID: 12934967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mild cognitive impairment: a treatment at last?
    Allain H; Bentué-Ferrer D; Akwa Y
    Lancet Neurol; 2004 Nov; 3(11):643. PubMed ID: 15488455
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.
    Alva G; Grossberg GT; Schmitt FA; Meng X; Olin JT
    Int J Geriatr Psychiatry; 2011 Apr; 26(4):356-63. PubMed ID: 21312297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.